LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Pfizer

Închisă

SectorSănătate

22.82 1.06

Rezumat

Modificarea prețului

24h

Curent

Minim

22.45

Maxim

22.82

Indicatori cheie

By Trading Economics

Venit

2.6B

3B

Vânzări

-4B

14B

P/E

Medie Sector

16.732

56.602

EPS

0.92

Randament dividend

7.72

Marjă de profit

21.633

Angajați

81,000

EBITDA

2B

4.5B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+26.88% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

7.72%

2.45%

Următoarele câștiguri

29 iul. 2025

Data viitoare de dividende

13 iun. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-14B

131B

Deschiderea anterioară

21.76

Închiderea anterioară

22.82

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

Pfizer Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 mai 2025, 18:41 UTC

Principalele dinamici ale pieței

Arvinas Shares Drop; Cancels Two Drug Trials With Pfizer Amid Capital Markets Challenges

29 apr. 2025, 11:24 UTC

Câștiguri

Pfizer 1Q Revenue Slides as Paxlovid Sales Fade

15 mai 2025, 15:20 UTC

Top știri

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

12 mai 2025, 22:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 mai 2025, 18:45 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- Update

12 mai 2025, 17:14 UTC

Top știri

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- WSJ

12 mai 2025, 09:02 UTC

Acțiuni populare

Stocks to Watch: Amazon, Tesla, Apple, Maersk -- WSJ

7 mai 2025, 17:01 UTC

Top știri

Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says -- Barrons.com

7 mai 2025, 09:30 UTC

Top știri

Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better. -- Heard on the Street -- WSJ

5 mai 2025, 15:13 UTC

Market Talk
Câștiguri

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

1 mai 2025, 14:07 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 11:58 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 11:06 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

1 mai 2025, 10:48 UTC

Câștiguri

Eli Lilly Earnings Beat Expectations. The Stock Is Falling. -- Barrons.com

29 apr. 2025, 19:47 UTC

Câștiguri

Pfizer Shares Rise on CEO's Optimism on Threatened Drug Tariffs -- Barrons.com

29 apr. 2025, 18:11 UTC

Câștiguri

Pfizer Stock's 7% Yield Makes It Look Like a Junk Bond -- But Better -- Barrons.com

29 apr. 2025, 15:22 UTC

Câștiguri

Pfizer Earnings Beat Isn't Enough to Ease Stock Worries -- Barrons.com

29 apr. 2025, 12:03 UTC

Achiziții, Fuziuni, Preluări

Pfizer Files 8K - Costs of Exits Or Disposals >PFE

29 apr. 2025, 11:46 UTC

Câștiguri

Pfizer Stock Gains After Earnings Beat. Tariffs Aren't the Only Worry for Wall Street. -- Barrons.com

29 apr. 2025, 11:42 UTC

Câștiguri

Pfizer Stock Falls After Earnings Beat. Tariffs Aren't the Only Worry. -- Barrons.com

29 apr. 2025, 11:12 UTC

Câștiguri

Pfizer Earnings Beat. Tariffs Uncertainty Hinders Guidance. -- Barrons.com

29 apr. 2025, 10:52 UTC

Câștiguri

Pfizer: Currently Trending Towards Upper End of 2025 Adj EPS Guidance Range

29 apr. 2025, 10:51 UTC

Câștiguri

Pfizer: Believe We Can Be Agile in Navigating Uncertain and Volatile External Environment

29 apr. 2025, 10:50 UTC

Câștiguri

Pfizer: On Track For Total Net Cost Savings $5.7B Through 2027

29 apr. 2025, 10:47 UTC

Câștiguri

Pfizer: Expects to Continue to De-Lever in Prudent Manner

29 apr. 2025, 10:47 UTC

Câștiguri

Pfizer: Current Fincl Guidance Does Not Anticipate Any Share Repurchases in 2025

29 apr. 2025, 10:46 UTC

Câștiguri

Pfizer: "Unable to Predict" Tariff Impact "At This Time"

29 apr. 2025, 10:45 UTC

Câștiguri

Pfizer: Reaffirmed Views Don't Currently Include Impact From Tariffs

29 apr. 2025, 10:45 UTC

Câștiguri

Pfizer 1Q EPS 52c >PFE

29 apr. 2025, 10:45 UTC

Câștiguri

Pfizer 1Q Adj EPS 92c >PFE

Comparație

Modificare preț

Pfizer Așteptări

Obiectiv de preț

By TipRanks

26.88% sus

Prognoză pe 12 luni

Medie 27.94 USD  26.88%

Maxim 32 USD

Minim 24 USD

În baza a 18 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruPfizer - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

18 ratings

5

Cumpărare

13

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

22.855 / 23.85Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.